Tianyin Pharmaceutical Co., Inc. (TPI)

[Ecomike]

I have been watching this one for at least 2 years. Found this today:
Pope and other institutions are buying Tianyin Pharma? I wonder what they know?

I may finally buy a few shares here. On close watch now!!!

http://www.nasdaq.com/quotes/institutional-portfolio/pope-asset-management,-llc-96593

http://www.nasdaq.com/symbol/tpi/institutional-holdings

[mlkrborn]

Tianyin Pharma provides progress update on Qionglai Facility (QLF) construction (TPI) 0.49 -0.01 : QLF construction has met its July progress milestone and is on schedule to accomplish Phase I of the QLF project, which is the relocation of TPI's TCM pre-extraction plant by the end of calendar year 2012. The Company reaffirms the relocation budget assessment in total of $25 million for the project. The pre-extraction facility will conduct initial processing of TCM raw material, separation using alcohol or water precipitation, filtration, centrifugation, concentration and purification of TCM pharmaceutical ingredients which will be further processed for the production of mTCM at the formulation facility.

[surf1944]

5:40AM Tianyin Pharma provides further updates on its GMOL flagship product (TPI) 0.45 : Co provides further updates on the business development of TPI's flagship product: Gingko Mihuan Oral Liquid or GMOL, a prescription medicine that is used by physicians for cardiovascular diseases such as stroke, coronary heart diseases, and angina. GMOL was recently awarded Essential Drug List status in the City of Chongqing. Chongqing, located in southwest China, with a population over 30 mln and its status as the municipality directly under the jurisdiction of the PRC Government along with other major cities with the same status, Beijing, Tianjin and Shanghai which are located in the east coastal area are regarded one of the most attractive markets in pharmaceutical sales in China.

[surf1944]

6:07AM Tianyin Pharma provides updates on its GMOL flagship product; GMOL has been selected as an EDL drug in both Henan province and Shandong province (TPI) 0.70 : Co provided updates on the sales expansion of TPI's flagship product: Gingko Mihuan Oral Liquid or GMOL. Under the ongoing healthcare reform policy that favors the sale of products that are listed in the Essential Drug List (EDL) in China, the national or provincial EDL listing could substantially support the market development of these products. GMOL has been recently selected as an EDL drug in both Henan province and Shandong province (with combined population of ~ 200 million) EDL provincial supplementary lists. The EDL status grants a full insurance coverage or 100% government reimbursement for patients.

[surf1944]

TPI 2011 Shareholder Annual Meeting Reminder: April 11, 2012 in New York
PR NewswirePress Release: Tianyin Pharmaceutical Co., Inc. – 7 hours ago:

CHENGDU, China, April 9, 2012 /PRNewswire-Asia/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced the reminder that the Company's 2011 Annual Shareholder Meeting will be held at Floor 20, 17 State Street, New York, NY 10004 on Wednesday, April 11, 2012, at 10:00 am (EST). February 13, 2012 is the record date for determining the stockholders entitled to vote at the annual meeting. Stockholders as of the record date are welcome to attend the meeting at the address above-mentioned, or dial in at 712-432-0080 (access code: 512917#).

[Penny Roger$]

~ $TPI ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $TPI ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=TPI&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=TPI&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/TPI?
~ OTC Markets: http://www.otcmarkets.com/stock/TPI/company-info
~ Google Finance: http://www.google.com/finance?q=TPI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=TPI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=TPI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=TPI
Finviz: http://finviz.com/quote.ashx?t=TPI
~ BusyStock: http://busystock.com/i.php?s=TPI&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=TPI&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=TPI
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=TPI
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=TPI
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=TPI
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TPI
~ MarketWatch: http://www.marketwatch.com/investing/stock/TPI/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=TPI
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TPI
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TPI&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TPI&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TPI&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[surf1944]

TPI Receives GMP Certification for JCM Facility
PR NewswirePress Release: Tianyin Pharmaceutical Co., Inc. – Wed, Jan 18, 2012 11:28 AM EST


CHENGDU, China, Jan. 18, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced the Company has received the Good Manufacturing Practice (GMP) certification for its 250-ton Jiangchuan Macrolide Facility (JCM) designated as "CHUAN M0799" valid through the period of December 31, 2011 until December 31, 2015.

Detailed information of the GMP certification for JCM facility can also be found in the official site of Sichuan Food and Drug Administration (www.scfda.gov.cn/ (Chinese version)).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: http://www.tianyinpharma.com

[FUNMAN]

Plenty more of insider buying has gone on since then too.

[lifter]

the Ceo buying a few thousand dollars worth of shares isnt a huge investment IMO. I hope I am wrong for those who are in this but this pig keeps getting bled out. I will take my loss and move on

[Ecomike]

LOL, you may have bought and sold too soon. The CFO just bought 4000 shares at .88, here is the Form 4! Looks like an early buy signal to me, but I am still watching this one from the side lines.

http://ih.advfn.com/p.php?pid=nmona&article=50113206

[lifter]

well that was costly, forgot I held this turd and glad I only lost $500 in selling today

[lifter]

got 3k @.99

[mlkrborn]

TPI Reports First Quarter Fiscal Year 2012 Financial Results
PR NewswirePress Release: Tianyin Pharmaceutical Co., Inc. – 10 hours ago


* Tianyin Pharmaceutical Co., Inc.

RELATED QUOTES
Symbol Price Change
TPI 1.02 -0.17

CHENGDU, China , Nov. 14, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012.

First quarter fiscal year 2012 ending September 30 , 2011 financial highlights

* 1Q FY2012 revenue decreased 20.5% year over year to $17.5 million from $22.0 million in 1Q FY2011,
* 1Q FY2012 operating income delivered $2.2 million , decreasing 52.2% from $ 4.6 million in 1Q FY2011,
* Net Income decreased 55.9% to $1.5 million from $3.4 million in 1Q FY2011,
* Earnings per share of $0.05 per basic share, or $0.05 per diluted share, compared with $0.12 per basic share, or $0.11 per diluted share in 1Q FY2011,
* Cash and cash equivalents totaled $33.3 million on September 30, 2011 ,
* Operating cash flow of 1Q FY2012 improves to $3.6 million , 140% gain from 1Q FY2011.

[lifter]

on watch here 99-1.01

[$King]

TPI @ 1.01

[surf1944]

TPI to Develop New Formulation for Flagship Product Gingko Mihuan

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Thursday November 3, 2011, 11:29 pm EDT

CHENGDU, China, Nov. 3, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) today announced the formulation expansion program for its flagship product Gingko Mihuan Oral Liquid (GMOL, SFDA certification number: H20013079; patent number: 20061007800225). GMOL, the proprietary prescription medicine for TPI with averaged annual revenue of $22 million, is used nationwide in China to treat brain ischemia and infarction, coronary heart diseases, memory dysfunction and other neurological disorders.

Major components in the Gingko extracts are flavonoids and terpenoids. Flavonoids consist of ginkgoflavone glycoside which are potent antioxidant that reduce capillary fragility which was frequently observed in cardiovascular disorders. Terpenoids consist of ginkgolides and bilobalide that inhibit platelet activating factor (PAF) which in consequence reduce the blood viscosity (Ma et al. J Nat Med. 2011; Maerz et al. Biosci Rep. 2011). GMOL also contains extracts from Gastrodia elata that were used for neurological symptoms such as epilepsy, headaches, dizziness and memory dysfunction (Tsai et al. J Ethnopharmacol. 2011; Kim et al. Molecules 2011).

The current oral liquid formulation for GMOL shows efficient absorption rate after intake, especially for elderly patients who are also afflicted with gastro-intestinal ailments. The new capsule form is more convenient to carry when travel and easy to use. In addition, the cost of production and packaging material prices for liquid formulation has been rising during the recent years. The new capsule formulation will reduce the overall cost of sales by 70% while extending the expiration period to 3 years from the current 2 years for oral liquid form. The new capsule formulation is expected to support the revenue growth of GMOL at approximately 30% year over year and improving the gross margin of GMOL products to 75% or higher. TPI will also apply for patent protection for the new capsule formulation. The research and development cost is estimated at $1-2 million. TPI expects to begin production of the new capsule formulation in approximately 12-15 months.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI and GMOL, please visit: http://www.tianyinpharma.com and www.sfda.gov.cn (Chinese version).

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit: http://www.tianyinpharma.com, or email [e-mail]
Tel: [phone] (Chengdu, China)
[phone] (China)
Address:
Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041
China

[surf1944]

JCM Begins Operation and Aims for GMP certification in November

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Monday October 24, 2011, 11:03 am

CHENGDU, China, Oct. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in the development and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) announced that the Jiangchuan Macrolide Facility (JCM) has began its operation manufacturing Azithromycin raw material.

The Company is targeting for Good Manufacturing Practice (GMP) inspection and certification in November.

About GMP

GMP are a set of comprehensive quality management systems required for pharmaceutical manufacturing covering the manufacture and testing of pharmaceuticals including APIs, diagnostics, foods, pharmaceutical products, and medical devices. GMPs are guidelines that outline the aspects of production that ensure the quality of a product.

GMP certification is conducted based on several underlying basic principles: 1) Clearly defined manufacturing processes that are controlled with critical processes validated to ensure consistency and compliance with specifications during the production; 2) Good Documentation Practices; 3) Operators are trained to carry out and document procedures; 4) Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were carried out and that ensure the quantity and quality of the drug; 5) Records of manufacture and distribution that trace the complete history of a batch are retained in a comprehensible and accessible form. 6) The distribution of the drugs minimizes any risk to their quality; 7) A system is available for recalling any batch of drug from sale; 8) Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence.

[BigOnChina]

Earnings report is SOLID! Stock should move in the right direction today.

[surf1944]

http://www.quotemedia.com/results.php?qm_symbol=tpi

[Ecomike]

This is a real good write up today of what is really going on, and why the shorts were so successful with the timing of their attacks on China based, RM US stocks like TPI, and why they have been so successful with the damage they caused to the entire sector, and why we have an uphill battle ahead. It is because they are between a rock and hard place. The problem is differences in US and China laws. READ all the way to the end, below!:

NEW YORK (Reuters) - Alarmed by widening accounting debacles at U.S.-listed Chinese companies, American regulators are scrambling to stem the damage from gaps in laws adopted to protect investors after the Enron scandal a decade ago.

U.S. investors had risked billions of dollars on hundreds of companies based in China - under a belief they were subject to U.S. rules when they sell and list shares in the United States - but a lot of that money has gone up in smoke.

The accounting blowups have humbled some prominent American investors such as top hedge fund manager John Paulson and former AIG CEO Maurice "Hank" Greenberg, spawned lawsuits and prompted a broad investigation by U.S. regulators.

Since March alone, more than two dozen U.S.-listed Chinese companies have announced auditor resignations or accounting problems, and there have been similar blowups in Canada.

Regulators and exchanges also have appeared flat-footed in the face of the growing scandal.

U.S. laws, including the sweeping 2002 Sarbanes-Oxley reform act meant to root out accounting fraud, lose some of their power with Chinese-based entities. The U.S. has no extradition treaty with China and the evidence gathering process in China is impeded by state secrets laws.

"The Chinese accounting problem has been festering for a long time," said Duke University law professor Jim Cox, who serves on a standing advisory group of the Public Company Accounting Oversight Board (PCAOB), which was set up under Sarbanes-Oxley to oversee accounting firms, including doing thorough inspections of their work.
Thwarted by state laws?

"It's going to get worse before it gets better," said Cox, who faults the U.S. Securities and Exchange Commission for not taking quicker action.

In particular, he said, the SEC has been slow to tighten oversight of U.S. shell companies acquired by Chinese firms through so-called "reverse mergers" to gain access to U.S. capital markets without having to go through an initial public offering.

SEC officials acknowledged problems with inspecting the accounting records of China-based companies well over a year ago at a meeting of the PCAOB advisory group, he said.

Meredith Cross, head of corporation finance for the SEC, said the agency has stepped up its reviews of Chinese reverse merger firms over the past year.

"We're currently thinking through whether there is more that we can do," Cross said.

A year ago, it launched a cross-border working group to review issues with Chinese reverse mergers and other companies with substantial foreign operations.

Officials from the SEC and PCAOB are holding talks with counterparts in Beijing this week in an attempt to get inspection access to Chinese auditors for U.S.-listed companies as one way to get on top of the problem.

But regulators said there is a core problem with tackling the reverse merger question head on because mergers come under state rather than federal law.

"We don't have a way to say, 'You can't do reverse mergers,'" said the SEC's Cross. "Because the issue of whether someone can merge is not an SEC question, but a matter of state law, it's not something where we could just wave a magic wand and say, 'we're not going to let reverse mergers happen anymore.'"

She did, though, note that such firms were bound by reporting requirements once they were listed.

The SEC also has resource constraints, she said, with about 350 people in its corporation finance division reviewing financial reports of more than 10,000 public companies. It has, though, been devoting more resources to the reverse mergers problem, she noted.

Further complicating matters, the SEC's Chinese counterpart, the China Securities Regulatory Commission, has no enforcement authority over many of the companies accused of fraud because they only sell shares in the United States.

Like other securities regulators, the CSRC has limited resources, said former SEC chairman Christopher Cox. "When triage is the name of the game, it's natural that the home country's priority is protecting its own citizens."

The SEC has brought several actions against China-based issuers in recent years. In most cases, action consisted of suspending trading or revoking companies' registration, though more severe penalties were also pursued.

China Energy Savings Technology Inc and its managers were ordered by a federal court in 2009 to pay a $34 million judgment after being charged with a stock manipulation scheme by the SEC.

Chinese courts typically do not enforce U.S. judgments, though at least $4 million will be recovered in that case because the SEC froze assets in the United States.
Access to work papers difficult

Accounting misconduct fell dramatically in the United States after authorities cracked down on corporate crime in the wake of the Enron and WorldCom frauds. A section of Sarbanes-Oxley that made it a felony for executives to certify false financial statements was one big deterrent.

That provision applies to companies that sell securities in U.S. markets, whether they are based in the United States or another country, but few Chinese executives fear being led away in handcuffs because of the lack of an extradition treaty, lawyers said.

"If you're a CEO of a company based in China and sign a false Sarbanes-Oxley certification, it's very difficult for the U.S. government or Justice Department to charge you with that crime, indict you and bring you to justice," said Phillip Kim, attorney at the Rosen Law Firm. "There are no treaties that provide for that."

Some Chinese executives resist answering to U.S. authorities at all, auditors said.

"They believe they should not have to respond if they feel any request is too intrusive and believe that they can tell the SEC no," Mimi Justice, head of Deloitte's forensic and dispute practice in Orange County, California said at a recent conference in Los Angeles.

Getting auditors' work papers -- crucial evidence in many accounting frauds -- has been especially difficult. Many accounting firms would like to hand over records but fear violating China's state secrets law, attorneys said.

"They have a real dilemma on their hands as to how to respond to the U.S. regulators when to do so might expose them to criminal sanctions in China," said Alan Linning, a partner at Sidley Austin in Hong Kong.

Crashing share prices and the publicity surrounding them do, of course, have their own Darwinian way of making investors more vigilant. There is, for example, much less appetite for new Chinese listings now, and many of the earlier listings are little more than penny-stock wreckage.

But to some that just begs the question -- is the action from the regulators too little, too late?

"I think the public is looking for an SEC that is proactive and in front of these issues, and they have yet to do that in this instance," said Lynn Turner, a former chief accountant at the SEC.

(Additional reporting by Sarah N. Lynch, Rachel Armstrong and Clare Baldwin. Editing by Martin Howell)

[surf1944]

TPI Schedules Test Runs at Jiangchuan Macrolide Facility by End of July

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Friday July 8, 2011, 6:00 am EDT

CHENGDU, China, July 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that its 250-ton Jiangchuan Macrolide facility (JCM) is scheduled for its manufacturing test runs by the end of July.

The test runs prepare the production lines for the final Good Manufacturing Practice (GMP) certification process by conducting a series of operations and tests under actual or simulated operating conditions to verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.

The successful completion of the test runs will be immediately followed by the GMP certification at JCM.

About GMP

Good Manufacturing Practice (GMP), widely adopted worldwide, provide guidelines covering the manufacture and testing of pharmaceuticals and active pharmaceutical ingredients, diagnostics, foods, pharmaceutical products, and medical devices with the basic concepts that safeguard the health of the patient, producing a good quality medicine, medical devices or active pharmaceutical products. GMP guidelines are a series of general principles that are mandated during manufacturing. The context of GMP covers plant and equipment operation, personnel training, quality management, product safety and stability along with other aspects that ensure the quality the product (www.sfda.gov.cn, Chinese version).

[Ecomike]

Fear of all China stocks.

[BigOnChina]

i think you'd be smart to

[NoChance2WinBig]

Why is this PPS so low here? Looking to get in...

[surf1944]

TPI Submits Renewal Application for High Tech Enterprise Status

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Sunday June 19, 2011, 8:00 pm EDT

CHENGDU, China, June 19, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that the operating subsidiary of TPI, Chengdu Tianyin Pharmaceutical ("Chengdu Tianyin"), has submitted the application for the renewal of its High Tech Enterprise Status at Chengdu, Sichuan Province of China.

Chengdu Tianyin is a wholly foreign-owned enterprise incorporated in the PRC and subject to PRC Foreign Enterprise Income Tax ("FEIT") Law. Chengdu Tianyin has been entitled to the preferential tax treatment for opening up its production facility in Western China in Sichuan Province. The applicable reduced preferential state enterprise income tax rate under this policy is 15% until December 31, 2010. If Chengdu Tianyin's High Tech Enterprise Status can be successfully renewed, it will reduce the current enterprise income tax to 15% for another three years from the beginning of 2011 calendar year.

The management will provide the progress update regarding the application process.

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: http://www.tianyinpharma.com.

[BigOnChina]

More great news!

[surf1944]

3:27PM Tianyin Pharma signs Macrolide API International sales and marketing agreement ; forecasts $30 mln domestic Azithromycin API revenue in China for first year of operation (TPI) 1.50 +0.02 : Co signed sales and marketing agreement with RELATIONS International. The co forecasts $30 million domestic Azithromycin API revenue in China for the first year of operation from its Jiangchuan macrolide facility that has an annual manufacturing capacity of 250 tons. The international sales revenue from macrolide API is expected to contribute additional revenue for TPI.

[BigOnChina]

HUGE NEWS!!!

TPI to buyback up to 3 million common shares on the open market! To put it in perspective, that's 20% of the float and 10% of the total amount of shares!!!!

[BigOnChina]

TPI did pay a dividend as a pharmaceutical company as recently as 2009. I remember being on the conference call when they told us they were suspending it because they felt there would be a better use for the cash.

[Ecomike]

Thanks, I see now that it was a US software company in 2006, and some sort of merger, conversion to a China BioTech in 08, so with out the dividend, I am going to watch and wait for now, till the China sector Shorts turn around, and things settle down.

I already have plenty of stocks that are loosing share price right now, LOL.

[BigOnChina]

They canceled the dividend awhile back to preserve cash for possible aquisitions. It didn't thrill me but until they put it to work I'm going to have to reserve judgement.

The drug pipeline with TPI is extensive. I think there are nine more drugs waiting for approval if I'm not mistaken.

In my opinion, TPI is one of the best buys out there and fly's way under the radar. This was once a $4.00 stock that has simply been thrown out with the bathwater.

Back up the trailer and load up.....

[Ecomike]

I have been watching this one for a long while, thinking it has reached the undervalued screaming buy. Only problem is that it is a China stock, and the trend is sell, or worse if shorts or SEC decides to screw things up.

So I have some questions.

(1) How did this one go public in the US? R/M and thus suspect, or what?

Jiangbo (another China pharmatech) trading was halted a few days ago by Nasdaq, asking for info with little warning (at least non that I saw). (note the cheese there was getting temping there too, way oversold!!)

Was the last dividend canceled, or is the news of it just not listed on my Fidelity brokers data yet.

The PE and dividend (If unchanged) looks like a screaming buy here, but have not really looked all under the rug yet. Any bodies buried here, anything scary I have overlooked, except for 52 week new lows?

I really like that this one seems to have about 7% dividend??? Thus putting it in a different class, unless they dilute and go on a shopping spree, or cancel the dividend?

What am I missing, why is this one selling off?

[BigOnChina]

great news!

[surf1944]

7:33AM Tianyin Pharma Receives Production License for Its Anti-diabetic Drug Gliclazide Tablets from China's SFDA (TPI) 1.72 : Co announces it has received the production license for its anti-diabetic drug Gliclazide Tablets from China's State Food and Drug Administration. The national pharmaceutical certificate number for TPI's new Gliclazide Tablets is also issued: H20113233.

[surf1944]

You nearly always have to sell a huge bio tech chart gap, starting buying back into some TPI today....

[surf1944]

Tianyin Pharmaceutical Co., Inc. to Host Third Quarter of Fiscal Year 2011 Earnings Conference Call on Tuesday, May 17, 2011 at 9:00 a.m. ET

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Thursday May 12, 2011, 6:00 am EDT

CHENGDU, China, May 12, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals, today announced that the earnings conference call for the third quarter of fiscal year 2011 ending March 31, 2011 to be held at 9:00 a.m. ET on Tuesday, May 17, 2011.

Interested parties may access the call by dialing [phone] (U.S.), 1-480-629-9664 (International)

The conference ID is 4441371. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling [phone] (U.S.), 1-858-384-5517 (International), from 05/17/2011 at 12:00 Noon ET till 05/31/2011 at 11:59 pm ET.

Replay Pin Number: 4441371

This call is being web cast by ViaVid Broadcasting and can be accessed at ViaVid's website at the following link: http://viavid.net/dce.aspx?sid=0000869E

About Tianyin Pharmaceutical

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:




Investors Contact:




James Jiayuan Tong M.D. Ph.D.


Chief Financial Officer, Chief Business & Development Officer


Director


Tianyin Pharmaceutical Co., Inc.


Web: http://www.tianyinpharma.com


Email: [e-mail]


Tel: [phone] (Chengdu, China)


[phone] (U.S.)




Address:


23rd Floor Unionsun Yangkuo Plaza


No. 2, Block 3, South Renmin Road


Chengdu, 610041


China

[surf1944]

http://www.form4oracle.com/company/tianyin-pharmaceutical-co-inc-tpi/company-transactions?id=12336

[surf1944]

TPI Receives SFDA Approval for Its Anti-Diabetic Drug Gliclazide

Press Release Source: Tianyin Pharmaceutical Co., Inc. On Friday May 13, 2011, 7:00 am EDT

CHENGDU, China, May 13, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation).

Gliclazide is an oral anti-diabetic drug that is used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when diabetes could not be managed by proper dietary adjustment and exercise or when not suitable for insulin therapy.

TPI is anticipating that its Gliclazide Tablets to make its market entry in July this year.

About Diabetes Mellitus

Diabetes Mellitus, or Diabetes, is a group of metabolic diseases that are featured with high blood sugar with lack of insulin, or due to cells do not respond to the insulin that is produced. This high blood sugar causes the classical symptoms: polyuria (frequent urination), polydipsia (increased thirst) and polyphagia (increased hunger). Later complications include vascular disease, peripheral neuropathy, and predisposition to infection. Treatment for Diabetes includes diet, exercise, and drugs that reduce glucose levels, such as insulin and oral antihyperglycemic drugs. Prognosis for Diabetes varies with degree of glucose control. There are two main categories of diabetes -- type 1 and type 2, which can be distinguished by a combination of features. The terms including the age of onset (juvenile or adult) or type of treatment (insulin- or non-insulin–dependent) are no longer accurate because of overlap in age groups and treatments between disease types (www.merckmanuals.com).

[BigOnChina]

more good new from TPI...I love it!

[surf1944]

7:02AM Tianyin Pharma receives SFDA approval for its anti-diabetic drug Gliclazide (TPI) 2.25 : Co announces that it has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation) used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. Co is anticipating that its Gliclazide Tablets to make its market entry in July this year.

[BigOnChina]

just the china slide. Earnings were great. I'm trying to accumulate some shares at this level.

[Ecomike]

This just keeps going lower. Is there something we do not know, or is this just China stock aversion and momentum letting it slide?

[CHA$E]

TPI currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.


Conference call 10 AM est 3/21


Cheers

;)

[1level]

The Chinese Small Cap Sector - The Other Side of the Rain

Many of us in our posts here are comparing the miniscule market capitalization of many of the Chinese small cap companies to the otherwise much higher valuations warranted by the strong past performance and the strong growth forecasted into the future and then express frustration, suspicions and despair due to the huge dichotomy between these two values.

I find it screamingly obvious that the relationship between market values and fundamentals across this sector is broken according to any common norms or benchmarks. Please note that I am referring here mostly to Chinese companies that are focused on and operative within the Chinese domestic markets and have no export activity.

As an indicative example, please consider the price chart and the declining P/E Ratio of CNIT (China Information Technology, Inc.) throughout this crisis, beginning at its preceding top in October 2007:
During the period between October 2007 and February 2011 the EPS for the years 2007 until 2010 grew 2.2 fold from $0.33 to$0.73, a blistering compound annual growth rate of 30.3%, yet the share price declined by 56% from $10.5 to $4.6 and the P/E Ratio declined by 81% from 32.8 to 6.3, drawing better than words how the ascribed risk shoot up and the sentiment fell off a cliff to the bottom of the barrel. To date, there is no indication that CNIT's growth may weaken going forward.
In particular, the declining price pattern that started for CNIT in October 2009 and continued until end of February 2011 ($8.0 to $4.6) is highly typical across this entire sector's price behavior during the past year. Even more so if we consider the fact that during this later period the broad market continued to rally additional 22%.

Having made this broad observation, I find it reasonable to assert that the companies themselves are not to blame. The answer must lie elsewhere.

And if we understand that the crowd behavior and its sentiment drivers are where to look - given the recent dark wave of allegations with respect to the entire Chinese small cap sector as being systematically fraudulent - we get our answer.

Clearly, the worst financial crisis in recent history and the collapse it caused has impacted investor psyche in a big way. In these post-crisis times, having stared at the abyss not too long ago, we are still carrying post-traumatic types of emotional weaknesses that influence abnormally our investment mindset and practices.

As we human beings are being threatened and hurt, our rational and enlightened mind recedes into our emotional tribal mind, which recedes into our instinctive survival mind, all depending on the level of threat and despair. The effect on our common crowd behavior is as if our elevated cultural evolution receded to darker periods in our history. For in-depth understanding of our crowd behavior as investors I recommend reading the book "The Psychology of Technical Analysis" by Tony Plummer.

As simple examples to consider, we may develop distrust and animosity towards different and remote people and cultures (they become the enemy), and conspiracy theories are easy to develop and get a hold (all Reverse Mergers done by Chinese are suspects of fraud as part of a pervasive scheme).

We are all essentially subject to a natural law which organizes individual behavior through the influence of group activity. And fear is likely to drive most of us straight into the arms of the crowd. And as top traders know, the crowd always loses in the end.

In this unregulated online exchange of information and opinions we are all taking a part, any stranger can cast doubt and spread fear by making allegations without stating conflicts of interest or having tangible evidence. It is common knowledge that the Chinese belong to historically separate and unfamiliar culture and different behavior patterns and therefore could be easily misinterpreted and abandoned if indeed dark and primitive emotions emerge and govern the scene. So under such extreme distrust and licentious environment, who would risk investing in a Chinese small company that might very well turn the next day to be accused of fraud? During the past year it seemed to be as dangerous as walking in a minefield. The encounters between ruthless short traders who smelled the fear in the air and their sheep-like insecure pray culminated in a blood bath that has racked up devastating losses for many shareholders.

Yet those of us who are able to regain their rational and independent mind from the oppressive direction of the crowd, may very well assert firmly that the correct and wise broad perspective is that China is a phenomenal growth story that is based on nationwide systematic innovation and investments, flexible adaptation and fast learning, and efficient and tireless execution of the central government growth programs, and many of these able entrepreneurs who reached out to the Mecca of the capitalistic free world for the best of reasons, overcoming great obstacles, will grow their companies in unprecedented rates with almost zero debts in still highly lucrative and unsaturated huge domestic markets. And in contrast, the US economy still needs to reach the stage where it can stand on its own following the FED's $2 trillion money-printing program, and the necessity to reduce the astronomical deficits and escalating debt levels is a very tall order. For an enlightening reading about the Chinese civilization I recommend reading a series of articles http://www.historians.org/projects/giroundtable/Chinese/Chinese3.htm.

It should be acknowledged that by the end of 2011 the majority of these companies will be trading on Wall Street and reporting to the SEC for their fifth consecutive year, a sufficiently distanced time from the early days following their typical Reverse Merger debut.

This Reverse Merger debut (reverse IPO) is the single most highlighted indicator to pinpoint a fraudulent Chinese company according to the governing fraud conspiracy rhetoric. Yet many of these companies have already engaged top tier accountant and law firms and have substantially improved their transparency and timely reporting as well as having been qualified for up listing to senior exchanges. I find it absolutely absurd to conclude at this point in time that these companies came to Wall Street in droves just to cheat for five consecutive years and counting, manipulating top professionals and paying hundreds of thousands of dollars as fees each year just for keeping this grand scheme alive. And correct me if I'm wrong, none of the accused firms (e.g., HRBN, YONG, CBEH, CEU, CCME, CHBT, ONP, CGA, CAGC, CSKI, CHNG, altogether I believe no more than one or two dozen) were delisted or legally proven as fraudulent to date.

As a final remark with respect to the Chinese entrepreneurs who are ill treated almost to the level of scoundrels by the all too many bashers of late: It is worthwhile appreciating their deep cultural heritage as there is a very real advantage of being part of the oldest living civilization. The values of culture and of being civilized have existed in China so long that they have soaked right through the whole people. Even a poor Chinese with no education is likely to have the instincts and bearing of an educated man. It is in their nature to set great store by such things as personal dignity, self-respect, and respect for others. And they have tremendous hunger and aptitude for education, which is one of the reasons why the future progress of China is likely to be amazingly rapid.

So as the problem lies in the crowd psychology domain, so does the solution. The distortion in the crowd behavior will be mended as this historic crisis continues to heal over the next several years and broad senses of normalcy and confidence are gradually restored. Time reveals truth and justice, and in this particular case the systematic and robust growth of the large majority of these companies will be depicted by the credibly audited financial statements. And the wave of fraud allegations will lose most of its hot air as there is a certain limit to how many times few can cry 'wolves' and they never really come.

A realistic and sound investment horizon that perhaps must be considered in order to benefit from the market capitalization recovery of this sector may be five years from today. I believe it is conservative to assume that many of these companies will grow their EPS by 15% to 20% per year and gradually be granted a P/E Ratio of 20 to 25. This implies that the Chinese small cap sector in all likelihood is a ten-bagger. We all can do our own calculus with respect to our chosen investment candidates based on our best analytical scrutiny. The key point here is that there will come the time when these Chinese companies will regain their credibility and be evaluated in full according to their consistent and dependable performance. It is my solemn observation that the dire sentiment has reached its nadir and it is only a question of time and an invisible match to fire it all up. Perhaps the time will be ripe later this year as 2010 10-Ks will be reported and 2011 estimates will be released and the first half results will be supportive of these estimates.

Good luck to all who are of the same line of independent thinking. It may very well spell an investment opportunity of a life time.

[BigOnChina]

TPI - Great numbers last quarter. Stock trades at $2.59 and has $1.11 in cash. The earned $0.14 this quarter, diluted, and are projecting 76% revenue growth and 50% net income growth in 2011!

I've gotta free up some cash monday morning for a nice purchase....

[BigOnChina]

my guess is lack of awareness by the investment community as well as the negative light being shed on china small cap stocks in general.

[Ecomike]

So why the sell off / flat price during a market rally last 3 months?

[Huggy Bear]

TPI is a quality company IMO. However, china stocks listed on the AMEX have a history of underperformance. That's my irrational only beef with TPI.

malc

[Talc Moan]

Yea, i will keep watch, and look for an entry point.

Smitter SMTT

[BigOnChina]

I think the bottom is more or less in. For a stock like TPI, it's going to sit between $2.68 and $2.90 until earnings news comes out.